Intervet/Schering-Plough launches Porcilis AR-T DF

Intervet/Schering-Plough has announced the launch of a new vaccine for swine which protects against progressive atrophic rhinitis.

Porcilis AR-T DF is designed as a replacement for the previous Porcilis AR-T offering, replacing the older product's oil-based adjuvant with an aqueous vitamin E-based agent.

This change is designed to improve the safety profile of the drug and lower the number of injection site reactions experienced by piglets, a benefit that has been proven in comparative field trials.

Atrophic rhinitis involves an inflammation of the nose mucosal tissue, which can cause this area of the animal to develop abnormally, leading to lower-weight animals and economic losses for farmers.

Marc Dickie, senior director for the global swine business unit at Intervet/Schering-Plough, said: "The new vaccine also demonstrates the commitment of our company to continuously improve our vaccines, thereby offering value-added benefits to our customers."

Last month, the company published positive data from a field trial of Porcilis PCV, its vaccine treatment for porcine circovirus-associated disease.